Samir Kaul

Samir focuses on health, sustainability, food, and advanced technology investments. Samir led the firm’s investments in Cadre, Guardant Health (NASDAQ: GH), Impossible Foods, Mojo Vision, NanoH2O (acquired by LG Chem), Nutanix (NASDAQ: NTNX), Oscar, Quantumscape, and Ultima,among others. Prior to co-founding Khosla Ventures, Samir spent five years at Flagship Ventures where he started and invested in early-stage biotechnology companies. While there, he was involved in co-founding Helicos BioSciences (IPO), a leader in developing single-molecule sequencing instruments to revolutionize personalized medicine, along with Stan Lapidus and Steve Quake of Stanford. Samir was also founding CEO of Codon Devices, where he raised their Series A financing, built the technical and advisory teams, and booked significant revenues in the company’s first year of operations. His other investments include Epitome (acquired by Millipore), LS9 (acquired by REG), and Morphotek (acquired by Eisai).